A prospective, multicentre, randmoised phase III study to evaluate the efficacy of ZOMETA [zoledronic acid] in preventing or delaying bone metastasis in patients with non-small cell lung cancer

Trial Profile

A prospective, multicentre, randmoised phase III study to evaluate the efficacy of ZOMETA [zoledronic acid] in preventing or delaying bone metastasis in patients with non-small cell lung cancer

Recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Mar 2006

At a glance

  • Drugs Zoledronic acid (Primary)
  • Indications Cancer metastases; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Mar 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top